Genetic Signatures has announced that the detection of influenza B is expected to influence its quarterly sales.

In response to the situation, Genetic Signatures (ASX:GSS) has undertaken an investigation.

The issue, which is unique to the influenza B virus, is reportedly close to being resolved.

It was revealed that this season’s influenza B virus is not being consistently detected in a low portion of samples with low viral concentrations.

At present, Genetic Signatures (ASX:GSS) expects its forecast revenue to approximate A$2 million for Q1 of FY2023.

Meanwhile, the detection of the influenza A virus remains unaffected.

In the meantime, the current quarter’s sales of Genetic Signatures' Easyscreen™ respiratory pathogen detection kit have been impacted.

Genetic Signatures (ASX:GSS) is a biotech firm that specializes in the development of diagnostics for the rapid detection of infectious diseases.